[NRajat]

Here are some of the latest updates on Amgen Inc.

• Product Collaboration between Amgen and Servier
  

Amgen Inc. declared a new collaboration with Servier on july,9,2013. With this collaboration Amgen has received an option to commercialize Servier's investigational molecule, S3884 for cardiovascular diseases in U.S. This molecule is studied for the treatment of heart failure diseases. Through this collaboration Servier's has also obtained rights to commercialize Omecamtiv Mecrabil (an activator of cardiac myosin). Under the terms of agreement between these two Amgen will make $50 million upfront payment. Servier is also very pleased to collaborate with Amgen, the globally leading biotechnology company.

For details, Click here

• Following are the recent job openings:
  

To apply, use the job ID and Apply here